Tumor-immune Evasion and Drug Resistance Therapies
Public on TASE Jul, 2013 Public on NASDAQ Jul, 2015
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Purple Biotech is a clinical-stage company that advances first-in-class therapies to overcome tumor-immune evasion and drug resistance. The companys goal is to create successful, long-lasting treatments for patients with hard-to-treat cancers.
Purple Biotechs oncology pipeline comprises two drugs: CM-24 and NT-219. CM-24 is a monoclonal antibody-blocking CEACAM1, a novel immune checkpoint that supports tumor-immune evasion and survival through multiple pathways. NT-219 is a potential first-in-class small-molecule bi-specific inhibitor of two key cancer resistance pathways: STAT3 and IRS1/2.
Prior to focusing on oncology, Purple Biotech developed Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. The drug was approved by the U.S. Food and Drug Administration for marketing in the United States in 2018. The company has also partnered to commercialize Consensi in China and South Korea.
In May 2020, Purple Biotech announced the commercial launch of Consensi in the U.S. by Burke Therapeutics, the marketing partner of its U.S. distributor, Coeptis Pharmaceuticals.